Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
Medical System Network Co., Ltd. (4350.T)
Sapporo, JP
Headquartered in Sapporo, Japan, and established in 1999, Medical System Network Co., Ltd. functions as a comprehensive provider within the healthcare industry. Its core business involves the distribution of pharmaceutical products to a diverse range of clients, including pharmacies, hospitals, clinics, and drug wholesalers. The company's operations are divided into several key segments. The Community Pharmacy Network division primarily facilitates the procurement and sale of pharmaceuticals among pharmacies, hospitals, clinics, and wholesale distributors. This segment also delivers crucial inventory management and liquidation services, manufactures and markets its own pharmaceutical offerings, and handles price negotiations with suppliers. Furthermore, it maintains a specialized platform designed to assist with pharmacy transitions. Within the Leasing and Facility-related segment, Medical System Network provides building rental services, develops optimal locations for new pharmacies, and offers consulting expertise to medical practitioners. The Meal Catering segment is responsible for delivering food services to hospitals and various welfare facilities. Beyond these primary areas, the company also offers nursing care and specialized advisory counseling services tailored for the medical treatment sector.
No mergers or acquisitions recorded for this company.
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| +1.74% | -10.34% | -13.17% | -14.29% | -8.06% | -9.48% | +4.23% | +18.18% | -33.33% | -15.68% | +318.31% |
Revenue flow
Revenue by geography
Revenue by segment
Revenue composition
By product
By geography
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
DCF figures are point estimates: small changes in growth or discount-rate assumptions move them materially. Read them as a reference, not a precise target.
| Rating | 2024-11 | Change |
|---|---|---|
| Strong Buy | 0 | 0 |
| Buy | 0 | 0 |
| Hold | 0 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
-
Revenue growth Medical - Pharmaceuticals: +7.8%+8.0% ★ Q1'26: +9.9% (vs Q1'25)
-
EPS growth Medical - Pharmaceuticals: +20.2%-15.2% Q1'26: +132.7% (vs Q1'25)
-
FCF margin FCF growth · Medical - Pharmaceuticals: +43.3%-5.2% Q1'26: +0.0% (vs Q1'25)
-
EBIT margin Medical - Pharmaceuticals: +6.8%+2.5% Q1'26: +2.8% (vs Q1'25)
-
ROIC Medical - Pharmaceuticals: +6.1%+4.2% Q1'26: +4.8% (vs Q1'25)
-
Share dilution Medical - Pharmaceuticals: +0.0%+0.0% Q1'26: 0.0% (vs Q1'25)
-
Debt / EBITDA Net debt/EBITDA · Medical - Pharmaceuticals: 0.21×11.37× Q1'26: 10.02× (vs Q1'25)
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
| Metric |
Mar 2015 actual |
Mar 2017 actual |
Mar 2018 actual |
Mar 2019 actual |
Mar 2020 actual |
Mar 2021 actual |
Mar 2022 actual |
Mar 2023 actual |
Mar 2024 actual |
Mar 2025 actual |
Mar 2026 1 Rev. Ana. 1 EPS Ana. |
Mar 2027 1 Rev. Ana. 1 EPS Ana. |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue |
75.55B
est: 75.00B (+0.7%)
|
88.87B
est: 90.00B (-1.3%)
|
93.98B
est: 95.00B (-1.1%)
|
98.23B
est: 98.00B (+0.2%)
|
105.24B
est: 105.00B (+0.2%)
|
104.26B
est: 103.30B (+0.9%)
|
106.69B
est: 106.50B (+0.2%)
|
109.55B
est: 109.50B (+0.0%)
|
115.36B
est: 114.20B (+1.0%)
|
122.39B
est: 122.20B (+0.2%)
|
128.00B
128.00B – 128.00B
+4.7% YoY
|
134.00B
134.00B – 134.00B
+4.7% YoY
|
| EBITDA |
4.65B
est: 4.56B (+1.9%)
|
4.72B
est: 5.48B (-13.8%)
|
5.71B
est: 5.78B (-1.2%)
|
4.20B
est: 5.96B (-29.6%)
|
3.29B
est: 6.39B (-48.5%)
|
7.18B
est: 6.29B (+14.2%)
|
7.05B
est: 6.48B (+8.8%)
|
6.25B
est: 6.66B (-6.2%)
|
6.90B
est: 6.95B (-0.7%)
|
6.42B
est: 6.37B (+0.8%)
|
6.67B
6.67B – 6.67B
+4.7% YoY
|
6.98B
6.98B – 6.98B
+4.7% YoY
|
| EBIT |
2.59B
est: 2.50B (+3.7%)
|
2.13B
est: 3.00B (-29.0%)
|
2.51B
est: 3.16B (-20.7%)
|
1.43B
est: 3.26B (-56.2%)
|
260.00M
est: 3.50B (-92.6%)
|
4.18B
est: 3.44B (+21.6%)
|
4.20B
est: 3.55B (+18.3%)
|
3.30B
est: 3.65B (-9.6%)
|
3.74B
est: 3.80B (-1.6%)
|
3.00B
est: 3.70B (-18.9%)
|
3.88B
3.88B – 3.88B
+4.7% YoY
|
4.06B
4.06B – 4.06B
+4.7% YoY
|
| Net Income |
885.85M
est: 1.15B (-23.3%)
|
571.00M
|
1.02B
est: 1.09B (-6.0%)
|
462.00M
est: 482.27M (-4.2%)
|
-896.00M
est: -239.67M (-273.8%)
|
2.20B
est: 1.93B (+13.9%)
|
2.39B
est: 2.28B (+5.1%)
|
1.61B
est: 1.40B (+14.8%)
|
1.86B
est: 1.90B (-2.1%)
|
1.26B
est: 2.15B (-41.3%)
|
2.60B
2.60B – 2.60B
+20.9% YoY
|
2.90B
2.90B – 2.90B
+11.5% YoY
|
| SGA |
20.17B
est: 25.18B (-19.9%)
|
25.62B
est: 30.22B (-15.2%)
|
27.97B
est: 31.90B (-12.3%)
|
30.00B
est: 32.91B (-8.8%)
|
31.69B
est: 35.26B (-10.1%)
|
33.16B
est: 34.69B (-4.4%)
|
34.51B
est: 35.76B (-3.5%)
|
36.51B
est: 36.77B (-0.7%)
|
37.45B
est: 38.35B (-2.3%)
|
46.45B
est: 42.40B (+9.5%)
|
44.42B
44.42B – 44.42B
+4.7% YoY
|
46.50B
46.50B – 46.50B
+4.7% YoY
|
| EPS |
37.08
est: 39.50 (-6.1%)
|
19.31
|
34.43
est: 37.20 (-7.4%)
|
15.22
est: 16.50 (-7.8%)
|
-29.49
est: -8.20 (-259.6%)
|
72.51
est: 66.00 (+9.9%)
|
79.35
est: 77.90 (+1.9%)
|
53.35
est: 48.00 (+11.1%)
|
61.86
est: 65.00 (-4.8%)
|
43.18
est: 73.60 (-41.3%)
|
89.00
89.00 – 89.00
+20.9% YoY
|
99.20
99.20 – 99.20
+11.5% YoY
|
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-08 | B+ | 3/5 | 5/5 | 3/5 | 3/5 | 1/5 | 3/5 | 4/5 |
| 2026-05-07 | B+ | 3/5 | 5/5 | 3/5 | 3/5 | 1/5 | 3/5 | 4/5 |
| 2026-05-01 | A- | 4/5 | 5/5 | 3/5 | 4/5 | 1/5 | 3/5 | 4/5 |
| 2026-04-30 | A- | 4/5 | 5/5 | 3/5 | 4/5 | 1/5 | 3/5 | 4/5 |
| 2026-04-28 | A- | 4/5 | 5/5 | 3/5 | 4/5 | 1/5 | 3/5 | 4/5 |
| 2026-04-27 | A- | 4/5 | 5/5 | 3/5 | 4/5 | 1/5 | 3/5 | 4/5 |
| 2026-04-24 | A- | 4/5 | 5/5 | 3/5 | 4/5 | 1/5 | 3/5 | 4/5 |
| 2026-04-23 | A- | 4/5 | 5/5 | 3/5 | 4/5 | 1/5 | 3/5 | 4/5 |
| 2026-04-22 | A- | 4/5 | 5/5 | 3/5 | 4/5 | 1/5 | 3/5 | 4/5 |
| 2026-04-21 | A- | 4/5 | 5/5 | 3/5 | 4/5 | 1/5 | 3/5 | 4/5 |
| 2026-04-20 | A- | 4/5 | 5/5 | 3/5 | 4/5 | 1/5 | 3/5 | 4/5 |
| 2026-04-17 | A- | 4/5 | 5/5 | 3/5 | 4/5 | 1/5 | 3/5 | 4/5 |
| 2026-04-16 | A- | 4/5 | 5/5 | 3/5 | 4/5 | 1/5 | 3/5 | 4/5 |
Owner Earnings
Ownership Overview
Ownership breakdown not available.
No beneficial ownership filings recorded.
Institutional Activity (13F)
Institutional history not available.
Top holders not available.
ETF Ownership
| # | ETF | Weight | Est. AUM exposure | TER |
|---|---|---|---|---|
| 1 | Amundi Japan TOPIX II UCITS ETF EUR Dist JPNU.L | 0.00% | 16.9K | 0.45% |
| 2 | Dimensional - International Small Cap ETF DFIS | 0.00% | 82.0K | 0.39% |
| 3 | iShares Core TOPIX ETF 1475.T | 0.00% | 166.5K | 0.05% |
| 4 | Dimensional - International Core Equity 2 ETF DFIC | 0.00% | 69.4K | 0.22% |
| 5 | Dimensional World ex U.S. Core Equity 2 ETF DFAX | 0.00% | 49.8K | 0.28% |
| 6 | Dimensional International Sustainability Core 1 ETF DFSI | 0.00% | — | 0.24% |
Insider Activity
No insider activity available.
Insider history not available.
No recent insider transactions.
Executive team
Executive compensation
Executive compensation not available.
No CEO compensation history available.
Proxy statements
No proxy statements available for this company yet.
Recent SEC filings
No SEC filings available for this company yet.
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Akira Aoyama | Managing Executive Officer, GM of System Headquarters & Director | — | male |
| Eiji Hirashima | GM of Accounting and Finance Division, Managing Executive Officer & Director | — | male |
| Inao Tajiri | President & Representative Director | — | male |
| Jiro Akino | Executive Vice President & Director | — | male |
| Kazuhiko Sumi | Managing Executive Officer & Director | — | male |
| Kenji Shimizu | Executive Officer, GM of SCM Business Headquarters & Director | — | male |
| Kentaro Tako | Managing Executive Officer, GM of Corporate Strategy Division & Director | — | male |
| Makoto Sakashita | Senior Managing Executive Officer, GM of Medical & Welfare Support Div. & Director | — | male |
| Yoshihiro Tanaka | Executive Vice President & Representative Director | — | male |
No data available for this company.
No Senate trading activity found for this company.
No House trading activity found for this company.
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for 4350.T
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
